Device Authority strengthens position in machine identity and Zero Trust Security

Tern plc

Device Authority has been named as a representative vendor for IoT Authentication in two Gartner Hype Cycle reports for 2026, covering Digital Identity and Zero-Trust Technology.

The recognition supports the company’s positioning in machine identity security, certificate lifecycle automation and cryptographic trust. These areas are becoming more important as organisations manage growing numbers of connected devices, operational systems and software workloads.

Device Authority’s KeyScaler platform is designed to automate machine identity provisioning, certificate lifecycle management, cryptographic key management and security policy enforcement. The technology is used to establish and maintain trust between devices and systems without relying on manual processes.

This is particularly relevant in environments where large numbers of connected assets need to be authenticated and managed securely. These include industrial systems, operational technology, medical devices, connected products and automotive platforms.

As organisations adopt Zero Trust security models, machine identity becomes a more important part of access control. Zero Trust requires every user, device and system to be verified before access is granted. That increases the need for reliable digital identities and automated management of the certificates and keys that support them.

Device Authority’s technology addresses this requirement by helping organisations control machine identities at scale. Automation can reduce the risk associated with expired certificates, unmanaged credentials and inconsistent security policies across large device estates.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Search